Equities

Ningbo Menovo Pharmaceutical Co Ltd

603538:SHH

Ningbo Menovo Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.62
  • Today's Change0.61 / 6.09%
  • Shares traded1.38m
  • 1 Year change-36.67%
  • Beta0.2573
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments543754745
Total Receivables, Net406262303
Total Inventory613594580
Prepaid expenses142827
Other current assets, total18425548
Total current assets1,7591,8941,702
Property, plant & equipment, net1,9031,8281,645
Goodwill, net----23
Intangibles, net206172202
Long term investments480356341
Note receivable - long term------
Other long term assets------
Total assets4,4244,4194,001
LIABILITIES
Accounts payable357307284
Accrued expenses636354
Notes payable/short-term debt684657531
Current portion long-term debt/capital leases563279
Other current liabilities, total218303198
Total current liabilities1,3781,3621,147
Total long term debt760706755
Total debt1,5001,3951,366
Deferred income tax1410367
Minority interest8988227
Other liabilities, total867554
Total liabilities2,3272,3342,250
SHAREHOLDERS EQUITY
Common stock213213151
Additional paid-in capital583562587
Retained earnings (accumulated deficit)1,2561,275967
Treasury stock - common(23)(32)(28)
Unrealized gain (loss)------
Other equity, total666774
Total equity2,0962,0851,751
Total liabilities & shareholders' equity4,4244,4194,001
Total common shares outstanding211211209
Treasury shares - common primary issue2.062.812.43
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.